Ornithine Transcarbamylase Deficiency Treatment Market Size & Share 2026 - 2034

Ornithine Transcarbamylase Deficiency Treatment Market Size

The global ornithine transcarbamylase deficiency treatment market was valued at USD 800.2 million in 2025. The market is anticipated to grow from USD 827.7 million in 2026 to USD 1.2 billion in 2034, growing at a CAGR of 4.3% from 2025 to 2034.

The ornithine transcarbamylase (OTC) deficiency treatment market is witnessing steady growth, driven by the increasing diagnosis of ornithine transcarbamylase deficiency, the most common inherited urea cycle disorder (UCD), and continued advances in rare disease therapeutics. OTC deficiency disrupts the urea cycle, preventing the effective removal of ammonia from the body and resulting in life-threatening hyperammonemia that requires lifelong disease management.

According to the National Organization for Rare Disorders (NORD), OTC deficiency affects approximately 1 in 14,000 to 1 in 70,000 live births worldwide, with improved newborn screening, genetic testing, and greater clinical awareness enabling earlier diagnosis of both neonatal and late-onset cases, particularly among female patients. This expanding diagnosed patient pool is accelerating demand across the ornithine transcarbamylase OTC deficiency treatment market and the broader urea cycle disorder market.

Market growth is further supported by increasing investments in research and development focused on next-generation gene therapies, liver-directed precision medicines, enzyme replacement approaches, and ammonia-lowering therapies that aim to improve long-term clinical outcomes. In addition, favorable orphan drug regulations, accelerated approval pathways, and market exclusivity incentives from regulatory agencies continue to encourage innovation for rare metabolic disorders. Established therapies such as sodium phenylbutyrate and glycerol phenylbutyrate have strengthened the current treatment landscape, while emerging pipeline candidates are expected to expand therapeutic options and address significant unmet medical needs.

As precision medicine, advanced diagnostics, and novel gene-editing technologies continue to evolve, the ornithine transcarbamylase deficiency treatment market is expected to experience sustained growth, supported by stronger patient identification, improved treatment accessibility, and ongoing innovation in rare disease care.

Ornithine Transcarbamylase Deficiency Treatment Market Trends

The Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is witnessing steady growth as advances in precision medicine, gene therapy, and rare disease management improve outcomes for patients with ornithine transcarbamylase deficiency, the most common inherited urea cycle disorder. The rising adoption of personalized treatment strategies that target disease-causing genetic mutations is increasing demand for innovative therapies beyond conventional ammonia-lowering approaches.

At the same time, nitrogen-scavenging therapies, including sodium phenylbutyrate and glycerol phenylbutyrate, remain the standard of care for controlling hyperammonemia, supporting continued expansion of the ornithine transcarbamylase OTC deficiency treatment market. Clinical development of gene therapies, such as Ultragenyx’s investigational UX701, is further transforming the treatment landscape by addressing the underlying enzyme deficiency and offering the potential for durable, long-term disease correction.

Growth is also supported by expanding newborn screening programs, enabling earlier diagnosis and timely intervention that significantly improves patient outcomes. Next-generation formulations with enhanced tolerability, lower dosing volume, improved palatability, and fewer gastrointestinal side effects are driving higher treatment adherence, with studies demonstrating adherence rates exceeding 90% for newer therapies compared with older sodium phenylbutyrate formulations.

In addition, favorable orphan drug policies, reimbursement support, and accelerated regulatory pathways across Japan, South Korea, China, and initiatives such as the Shandong Province Rare Disease Drug List are improving patient access to OTC deficiency therapies and creating opportunities for both branded and generic products. Growing awareness campaigns led by rare disease advocacy organizations are further strengthening early diagnosis, clinical trial participation, and access to innovative treatments, reinforcing long-term growth across the global ornithine transcarbamylase deficiency treatment market.

Lastly, organizations such as the National Urea Cycle Disorders Foundation (NUCDF) and Global Genes are improving patient outreach, awareness, and fundraising for research and development. These organization helps boosts early recognition, clinical trial enrollment, and drug access globally, thereby contributing to market growth.

Ornithine Transcarbamylase Deficiency Treatment Market Analysis

Based on product, the global market is divided into Buphenyl, Ravicti, Ammonul, dietary supplements and other products. The Ravicti drug segment dominated the market and was valued at USD 305.6 million in 2025.
 

• Ravicti is a highly effective ammonia scavenger, designed to treat urea cycle disorders (UCDs) like OTC deficiency.
   
• Moreover, Ravicti is an odorless, tasteless liquid, making it more palatable and easier to administer, particularly for pediatric and elderly patients who often struggle with pill-based medications, contributing to their increased adoption.
   
• Furthermore, Ravicti has received approvals in multiple regions, including the U.S., Europe, and Asia-Pacific, broadening its availability to diverse patient populations. The FDA approved its use for children under two years old in 2017, significantly expanding the potential market.

Learn more about the key segments shaping this market

Download Free PDF

Based on the route of administration, the global ornithine transcarbamylase deficiency treatment market is categorized into oral and intravenous. The oral segment accounted for the highest market share of 62.3% in 2025.
 

• Oral drugs are more convenient compared to intravenous (IV) therapies, requiring less frequent hospital visits. This is particularly important for managing OTC deficiency, as it is a lifelong condition that requires regular treatment.
   
• Moreover, recent advancements in oral drug formulations, such as sustained-release or delayed-release mechanisms, have improved the bioavailability of active ingredients, making oral medications as effective as their IV counterparts. This trend contributes to the expansion of the treatment market as more individuals seek medical attention for such conditions.
   
• Furthermore, oral formulations allow for flexible dosing, which can be tailored based on patient needs, improving treatment customization for managing OTC deficiency.
   

Based on the age group, the global ornithine transcarbamylase deficiency treatment market is categorized into pediatric and adult. The pediatric segment dominated the market in 2025 and is anticipated to grow with a CAGR of 4.4% during the analysis period.
 

• Early diagnosis and awareness of OTC deficiency in neonates and children have significantly improved, contributing to timely treatment interventions. Early detection through newborn screening programs has helped identify affected infants before they experience severe symptoms, contributing the market growth.
   
• For instance, according to a 2021 study published in JAMA Neurology, newborn screening for metabolic disorders, including OTC deficiency, has increased in the U.S. by nearly 30% in the last decade, allowing early interventions and reducing complications associated with untreated OTC deficiency. Thus, the increasing diagnosis rate improved therapeutics, and a greater focus on rare pediatric diseases are shaping the future growth of the market.
   
• Moreover, the development of more effective, child-friendly treatment options for pediatric patients has driven the adoption of therapies, driving market growth.
   

Based on the distribution channel, the global ornithine transcarbamylase deficiency treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2025 and is anticipated to reach USD 554.6 million by 2034.
 

• OTC deficiency treatments often require personalized dosing and careful monitoring, which is best managed in hospitals where patients can be monitored by healthcare professionals. Hospital pharmacies provide the necessary expertise in managing complex regimens, especially for pediatric patients and those with severe symptoms.
   
• Additionally, hospital pharmacies play a central role in the compounding, dispensing, and administration of specialized medications like Ammonul (sodium phenylbutyrate), which is commonly prescribed for OTC deficiency. Pharmacists also provide counseling, helping ensure adherence to treatment regimens.
   
• Moreover, as treatments for OTC deficiency are high-cost therapies, reimbursement policies by governments and insurance companies often make hospital pharmacies the primary point for dispensing such medications, as they are covered under medical plans rather than retail pharmacy benefits drives the market growth.

The North America ornithine transcarbamylase deficiency treatment market dominated the global market with a market share of 45.3% in 2025. The market is driven by high awareness and access to specialized metabolic disorder centers, higher incidence in North America due to carrier detection and family testing and strong industry presence and supply chain integration.
 

The U.S. market size reached USD 326.1 million in 2025, growing from USD 315.6 million in 2024.
 

• The increasing healthcare expenditure in the U.S. ensures that patients with rare diseases like OTC deficiency have better access to treatments, either through public healthcare systems or private insurance, that further contribute to market growth.
   
• Moreover, the increasing number of collaborations between pharmaceutical companies, research institutions, and biotech firms is accelerating the development of treatments for rare diseases like OTC deficiency. contributes to the growth of the treatment market.
   
• Furthermore, in the U.S., the FDA’s Orphan Drug Act incentivizes the development of treatments for rare diseases, which has resulted in expedited drug approvals for OTC deficiency treatments. Government initiatives provide funding and incentives for research in this field.
   

Europe ornithine transcarbamylase deficiency treatment market accounted for USD 205.2 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Many European countries are increasingly incorporating urea cycle disorders (UCDs) into mandatory newborn screening panels. For instance, Germany, Italy, and the Netherlands have added ammonia-related metabolic disorders to their panels.
   
• This has led to early diagnosis, which increases lifetime patient value through early initiation of chronic therapies like Ravicti, Buphenyl, and amino acid supplements.
   
• Moreover, emerging biotech’s in Europe (e.g., Orchard Therapeutics) and partnerships with US-based rare disease companies signal strong licensing interest in Europe.
   
• Expanding pipeline drugs for OTC, such as AAV-based gene therapies, are expected to enter early access or compassionate use programs by 2026–2028., thereby aiding market growth.
   

Germany shows strong growth potential in the ornithine transcarbamylase deficiency treatment market.
 

• The German government, through the AMNOG (Act on the Reform of the Market for Medicinal Products), offers favorable reimbursement policies for orphan drugs, making OTC deficiency treatments more accessible to patients. This support enhances the adoption of novel therapies in clinical settings and drives the market growth.
   
• Moreover, Germany has an aging population, which increases the demand for healthcare services. As more individuals with UCDs survive into adulthood due to better treatment options, the demand for ongoing management of OTC deficiency in adult populations is rising.
   
• Furthermore, Germany's medical community is highly active in rare disease awareness, and numerous organizations (such as the German Society for Pediatric Metabolism and Endocrinology) work to educate healthcare providers about OTC deficiency and its treatment options contributing to market growth.
   

The ornithine transcarbamylase deficiency treatment market in Asia Pacific is estimated to grow at a CAGR of 4.7% over the next few years.
 

• The expansion of healthcare system, including specialized medical centers and hospitals, particularly in developing economies, has improved the availability of treatments for rare diseases like OTC deficiency.
   
• Moreover, with improvements in genetic screening and awareness, more cases of OTC deficiency are being diagnosed. OTC deficiency is a rare genetic disorder caused by mutations in the OTC gene, leading to an inability to metabolize ammonia.
   
• Furthermore, several new therapeutic options for OTC deficiency are being introduced in the Asia Pacific market. Additionally, treatments such as sodium phenylbutyrate (used to lower ammonia levels) and gene therapies are gaining attention due to their ability for managing or curing the disorder and improving the quality of life for affected individuals, thereby contributing to market growth.
   

China ornithine transcarbamylase deficiency treatment market is predicted to grow significantly over the forecast period.
 

• Rising availability of newborn screening and genetic testing. In addition, private companies such as BGI Genomics offer whole exome sequencing (WES) and next-generation sequencing (NGS) for urea cycle disorders.
   
• Earlier diagnosis enables timely treatment initiation, increasing demand for long-term drugs like glycerol phenylbutyrate and arginine/citrulline.
   

Brazil's ornithine transcarbamylase deficiency treatment market is projected to witness growth in coming years.
 

• OTC deficiency is a rare inherited disorder, but it is still a significant concern for the Brazilian population, as it is a genetic disorder that can be present across various regions. The prevalence of urea cycle disorders, including OTC deficiency, is estimated to be around 1 in 40,000 live births worldwide. Brazil’s population size (approximately 213 million) contributes to a notable number of affected individuals, which drives the demand for treatment options.
   
• Furthermore, Brazil has seen a steady rise in healthcare spending over the past decade, especially in private healthcare sectors. This has improved access to rare disease treatments and advanced therapies, creating a growing demand for OTC deficiency treatments, that contribute to market growth.
   

Saudi Arabia is anticipated to grow in the Middle East and African ornithine transcarbamylase deficiency treatment market.
 

• OTC deficiency, a genetic disorder affecting the urea cycle, has gained more attention in Saudi Arabia in recent years due to enhanced awareness campaigns and genetic counseling programs. This has resulted in more diagnoses of OTC deficiency, which drives demand for effective treatment options.
   
• Moreover, Saudi Arabia has established specialized centers for genetic disorders and rare diseases, offering advanced treatment options for OTC deficiency, such as the use of nitrogen-scavenging drugs and liver transplant services.
   

Ornithine Transcarbamylase Deficiency Treatment Market Share

Competition in the ornithine transcarbamylase deficiency treatment industry is marked by well-established companies, emerging firms, and local players fighting to capture a larger share of the market. The top 5 players such as Ultragenyx Pharmaceutical Inc, Acer Therapeutics, Nutricia (Danone Group), OrphanPacific, and Mead Johnson Nutrition (Reckitt Benckiser) account for approximately 62% of the global market. These key players focus on various strategies such as acquisitions, business expansion and novel product launches to consolidate their market presence.
 

Additionally, there are several local and regional players operating in the market who are boosting competition by providing affordable therapeutics at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offering. The competitive landscape in the market is characterized by a mix of global pharmaceutical companies and regional players. Established pharmaceutical giants offer well-known ornithine transcarbamylase deficiency treatment under various brand names. Companies are focusing on product differentiation, regulatory approvals, and strategic partnerships to strengthen their position in this competitive market.
 

Ornithine Transcarbamylase Deficiency Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

• Abbott Laboratories
• Acer Therapeutics
• Amgen
• Arcturus Therapeutics
• Bausch Health Companies
• Nutricia (Danone Group)
• Mead Johnson (Reckitt Benckiser)
• Nestle
• OrphanPacific
• Ultragenyx Pharmaceutical 
   
• Ultragenyx is a leading player in the OTC deficiency market, recognized for its strong rare disease portfolio and commitment to patient-centric solutions. The company’s flagship product Ravicti (glycerol phenylbutyrate) offers chronic, oral, ammonia control with improved palatability and tolerability, especially in pediatric populations.
   
• Acer Therapeutics differentiates itself with a reformulated oral sodium phenylbutyrate product (ACER-001), developed to address taste and tolerability issues associated with existing ammonia-scavenging therapies. The company is focused on low-cost, high-value innovation in rare diseases and works with regulators in both the U.S. and Europe to expedite access under orphan drug pathways.
   
• Nutricia, a division of Danone Group, is a global leader in metabolic nutrition, providing specialized medical foods for urea cycle disorders including OTC deficiency. The company collaborates with metabolic clinics and pediatricians to tailor nutritional plans for patients with genetic and enzymatic deficiencies.

Ornithine Transcarbamylase Deficiency Treatment Industry News

• In January 2025, Precision BioSciences announced that its partner iECURE reported clinical efficacy and safety data from the first patient treated with ECUR-506 in the Phase 1/2 OTC-HOPE study. ECUR-506 is an in vivo gene insertion therapy for neonatal-onset Ornithine Transcarbamylase (OTC) deficiency that utilizes Precision's licensed PCSK9-specific ARCUS nuclease. The first infant achieved a complete clinical response, discontinued ammonia scavenger medication after 12 weeks, maintained normal ammonia levels through 6 months, and the OTC-HOPE trial remained on track to complete enrollment in 2025 with a full data readout expected in H1 2026.
   
• In May 2025, Precision BioSciences provided a business update confirming that the first ECUR-506 patient continued to demonstrate a complete clinical response more than one year after treatment. The company stated that clinical data had been presented at the 2025 ACMG Annual Clinical Genetics Meeting, additional data were accepted for presentation at ASGCT 2025, and the OTC-HOPE trial was continuing across the U.S., U.K., Australia, and Spain, with enrollment expected to finish in 2025 and complete study data anticipated in the first half of 2026.

The ornithine transcarbamylase deficiency treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Buphenyl
• Ravicti
• Ammonul
• Dietary supplements
• Other products

Market, By Route of Administration

• Oral
• Intravenous

Market, By Age Group

• Pediatrics
• Adults

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE